Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab)

• Catalog Number: orb1806363
• Category: Antibodies
• Description: Anti-CTLA-4 / CD152 Reference Antibody is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.2 kDa.
• Clonality: Monoclonal
• Tested applications: ELISA, FA, FACS, Kinetics
• Reactivity: Human
• Isotype: IgG
• Purity: > 95%
• Conjugation: Unconjugated
• MW: 145.2 kDa
• Target: CTLA-4 / CD152
• Endotoxins: < 1 EU/mg
• Storage: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
• Buffer/Preservatives: 100 mM Pro-Ac 20 mM Arg pH 5.0
• Note: For research use only
• Expiration Date: 12 months from date of receipt.

Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

The purity of Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab)is more than 99.37% ;determined by SEC-HPLC.

Human CTLA-4 & Human PD-1 CHO-K cells were stained with Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab) and negative control protein respectively; washed and then followed by PE and analyzed with FACS; EC925=0.2270 μg/mL.

Ipilimumab inhibited the tumor growth of MC38 on huCTLA-4 mice. The result showed significant anti-tumor effects; with an tumor inhibition rate (TGI) of 99.3% at 0.88 mpk at D37.